Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Recent trial of anti inflammatory with beneficial effect on development of cardiac and cancer events in NEJM and Lancet studies with relevance to Brilicidin due to the pathways it effects.
Brilicidin is an anti inflammatory drug which I hope in the near future will shortly be confirmed to decrease incidence and duration of oral mucositis ( in addition to antibiotic effects). The main inflammatory cytokines involved in development of oral mucositis are IL1B and TNF alpha which was mentioned in this article. https://www.revolvy.com/main/index.php?s=Oral%20mucositis. Brilicidin effects these cytokines http://www.ipharminc.com/new-blog/2017/6/1/brilacidins-mechanism-of-action-targeting-the-il-17-pathway . The CANTOS trial evaluated the antiinflammatory drug canakinumab, a monoclonal antibody neutralizing IL1B and found that not only did it lead to a lower rate of cardiovascular events then placebo http://www.nejm.org/doi/full/10.1056/NEJMoa1707914#article, but it lead to a marked reduction in the incidence of lung cancer and lung cancer mortality. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32247-X/fulltext. Of note, an increased risk of fatal infections was noted in about 1/1000 patients.
Brilicidin may have even greater utility then we realize in patients at risk for lung cancer and cardiac events.
Success is failure turned inside out
http://www.all-creatures.org/poetry/dontquit.html
Brilicidin decreases tnf alpha (see 2nd link) that has been linked to etiology of depression. Could Brilicidin have potential utility in the psychiatric field?
https://www.psychologytoday.com/blog/urban-survival/201701/new-research-shows-depression-linked-inflammation
http://www.ipharminc.com/new-blog/2017/8/7/brilacidin-for-oral-mucositis
Time to analysis of an actionable gene mutation in a tumor specimen @ Mary Crowley 27 to 30 days
https://www.marycrowley.org/groundbreaking-research/gene-mutations/
https://www.marycrowley.org/groundbreaking-research/cancer-pathways/
An old (negative)phase 3 study of pilocarpine for dry mouth in head and neck patients also looking at mucositis had 131 patients
https://www.ncbi.nlm.nih.gov/pubmed/12182969
I asked leo the same question as below. He did not directly say it crossed the BBB, but he did say kevetrin is a small molecule leading me to feel that he does believe it can cross the BBB.
I asked him the following:
I know kevetrin has shown potent antineoplastic activity against GBM. I have 2 questions regarding this. 1)Does kevetrin cross the blood brain barrier? 2) If not, has any thought been given to working with the Bioasis company http://www.bioasis.ca/ transcend/
to work on coupling kevetrin to an agent that would facilitate crossing the BBB?
Leo responded:
Our Kevetrin focus now (in the short term) is treating ovarian cancers and developing an oral formulation. Kevetrin is a very small molecule and treating GBM is of interest to us.
Thank you for your interest in Cellceutix.
Best wishes,
Leo Ehrlich
Old polymedix presentation attached including information on TB, malaria.
https://www.sec.gov/Archives/edgar/data/1341843/000095012309019149/c87437exv99w1.htm
Think of the potential if kevetrin 50% all cancers see article re keytruda
The FDA Has Never Approved a Drug Like This in Its 111-Year History
http://flip.it/lmAjEm
What do you predict price per share will be in one year?
Please see my post number 103339 regarding Leo's response to the question I posed regarding the use of B-OM in radiation proctitis etc.
Not producing news today feeds the shorts making them hyperactive. A great planned move would be to then hit them with partnership news or phenomenal prurisol results tomorrow, hitting them where it counts -in their trading accounts.
Xoc
With regards to use of Brilicidin OM to treat radiation cystitis and proctitis please see the old note I am now responding to regarding an old queation I had for Leo and his response about such potential for the drug.
This is the link to article on mucositis
http://www.ijbm.org/v4i4_1.html
Mucositis can last longer then the duration of radiation therapy - up to 84 d after onset of chemoradiation and beyond- see this article:
Duration of Mucositis: Far Longer than 2 to 4 Weeks and May Be Avoidable Altogether
www.ijbm.org › Article4(4)_Com1
by RW McCullough
Note the words "we plan to provide further scope and breakdown of study results across the first 2 cohorts". Could the word scope have a dual meaning here, meaning both extent/details and perhaps also pictures from endoSCOPic procedures?
Anyone who invested in this stock in the early years because of the science is basically forgotten by management. Early investors lost the bulk if their invested money because of extreme dilution.Management does not seem to care about the investor.
Isn't it interesting that the B-up trial is being held in an unknown location, almost as if a cda has been in place from the onset of this trial with a major pharma, to allow them to perhaps have direct oversight in this trial. It is feasible that results of the 2nd cohort in combination with the already good results of the first cohort are favorable enough to have the pharma reach a partnership deal even before the trial is complete. If that is the case we could be in a quiet period. It is unlikely that results are showing severe grade toxicity as during treatment for MRSA in the Brilicidin trial ,where there was great systemic absorption, such toxicity was not seen, and such an event would require immediate notification due to its material effect on Cellceutix. I remain optimistic and hope for great news shortly.
In 2014, Ella Ruth talked about using Bioasis transcend technology to couple kevetrin to an agent facilitating the crossing if the BBB.
http://seekingalpha.com/instablog/21116141-ellaruth/3071735-kevetrin-the-salt-that-is-worth-gold.
In2015, Bioasis entered a research collaboration with Brigham and Womens Hospital, using the Bioasis peptide carrier MTfp , lead by the Dr Sean Lawler Dept of neurosurgery at Harvard Medical School to test compounds targeting GBM across the BBB. Although kevetrin was not on the initial list of compounds to be tested, perhaps given prior relationships perhaps kevetrin was tested.
http://www.bioasis.ca/2015/07/21/bioasis-technologies-inc-and-brigham-and-womens-hospital-inc-enter-a-neuro-oncology-research-collaboration-agreement/
http://www.bioasis.ca/2017/01/23/bioasis-provides-agm-update-expanding-the-bioasis-deal-flow-pipeline/
Giavanni Martinelli is at the University of Bologna , participated in this:
http://www.bloodjournal.org/content/128/22/1675/tab-article-info?sso-checked=true
article on the ex vivo drug response profiling for AML, perhaps this profiling has been used to test kevetrin in combination with Cytarabine
I do not know if kevetrin can cross the BBB, however, if it does it could potentially help many desperate people now being treated with temodar and radiation, especially as kevetrin is a radiosensitizer.
Cellceutix has known about activity of kevetrin in GBM since 2012 -see press release below:
http://www.cellceutix.com/press-release/2016/11/17/cellceutix-adds-brain-cancer-to-growing-list-of-indications-for-its-novel-cancer-drug
PCYC sale was for 21 billion, not 11 billion. Does that change your numbers for CTIX?
I look forward to the B-OM BOOM
Arrayit reports $400,000 microarray services inquiry from advanced pharmaceutical leader Cellceutix CTIX Beverly MA https://t.co/ytPCwz1cbz https://t.co/vPe8vIBzIe
From Arrayit twitter feed
To clarify:
This Breakthrough In Biotech Has Enormous Investment Potential
http://flip.it/8W3IMQ
This article by Patrick Cox in Forbes 2/10/17 references why he is invested in this company.
The article I posted "This Breakthrough ..." in by Patrick Cox about BioTime and it's subsidiaries published in Forbes yesterday.
BioTime Acquires Retinal Repair Cell Therapy from UPMC | GEN Genetic Engineering & Biotechnology News - Biotech from Bench to Business | GEN
http://flip.it/Ud4UGE
This Breakthrough In Biotech Has Enormous Investment Potential
http://flip.it/-SD-fD
The ASCO abstract deadline was yesterday 2/7 for the meeting in June 2017. Will we see data presented at that meeting about the Kevetrin trial or Brilicidin OM?
According to the clinicsl trials site the kevetrin trial is anticipated to start Feb 9th , NEXT WEEK!
Sad story about child with p53/ li fraumeni induced GBM . Unclear now if kevetrin could cross BBB to help GBM patients.
http://stanmed.stanford.edu/2016fall/milan-gambhirs-li-fraumeni-syndrome.html
A happy wife is a happy life. What I wrote was just tongue and cheek venting, but unfortunately my wife dies not want me to add to my holding of shares. May all of our lives this New Year be filled with happiness,health and wealth from our CTIX investments.
XOC
My boss (wife) does not want me to buy additional shares. I do have a good investment already , but these,shares are so cheap I want more. How can I convince her that although this is by far not a conservative investment,that the potential benefits of this company are amazing and worth the additional risk? I feel that to a great extent it has been derisked due to prior early phase trial successes and wish she would let me buy more.
I cannot correct my notes to Ihub .Dermatologists deal with epithelium not the mucosa is what I meant to say.
Should have said dermatologists deal either epithelium not the mucosa.
The lips are excluded from the Brilicidin OM trial. dermatologists deal with epithelium, mother mucosa. This is not a dermatological trial.
I did not finish the note I was writing. The brilicidin OM trial is testing the effect of brilicidin on oral cavity mucosa not skin so I do not believe brilicidin om overlaps with dermatology .
The oral mucositis trial is testing brilicidin om oral cavity
Perhaps the infectious disease, GI and cancer circles could all overlap with oral mucositis, as mucositis is a cancer treatment side effect , and brilicidin has antiinflammatory as well as antibiotic efficacy.
Possible mistake in new site noted. The new site is great but should this be corrected - see below:
In the Venn diagram under therapeutic areas shouldn't oral mucositis be located between the infectious disease circle and the GI circle as Brilicidin is the agent for both of these trials. It should not rest between the dermatology and cancer circles, as Prurisol and kevetrin are not factors in the mucositis program?
http://www.cellceutix.com/therapeutic-areas/
Mega pharma mergers to happen in Trump USA:
Donald Trump's election to trigger new era of pharma mega-mergers
http://flip.it/8LQjQQ